MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
CFRX - ContraFect Corp
$5.81
0.31(5.64%)9:00:00 PM 2/24/2021
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. ContraFect Corporation has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. The company also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/11/2021CFRX
    ContraFect Announces Appointment of Dr. Jane F. Barlow to Board of Directors

    YONKERS, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs) as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the appointment of Jane F. Barlow, MD, MPH, MBA to the Company’s board of directors (Board). “Dr. Barlow is an expert in both market access and payer reimbursement for the healthcare indust...

    12/30/2020CFRX
    What Kind Of Shareholders Hold The Majority In ContraFect Corporation's (NASDAQ:CFRX) Shares?

    Every investor in ContraFect Corporation ( NASDAQ:CFRX ) should be aware of the most powerful shareholder groups...

    12/11/2020CFRX
    Is CFRX A Good Stock To Buy Now?

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

    11/24/2020CFRX
    CFRX: Enrollment Continues in Phase 3 Trial of Exebacase…

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Exebacase Expanded Access Program Initiated On October 26, 2020, ContraFect Corp. (CFRX) announced the initiation of an expanded access program for exebacase to make it available to COVID-19 patients that are suffering from persistent bacteremia caused by Staphylococcus aureus . Exebacase will be available to use

    11/13/2020CFRX
    ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update

    CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections Initiated expanded access program with exebacase for the treatment of persistent MRSA bloodstream infections in COVID-19 patientsYONKERS, New York, Nov. 13, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin ...

    10/31/2020CFRX
    Kaskela Law LLC Announces Stockholder Investigation of ContraFect Corporation - CFRX

    PHILADELPHIA, PA / ACCESSWIRE / October 31, 2020 / Kaskela Law LLC announces that it is investigating ContraFect Corporation ("ContraFect") (NASDAQ:CFRX) on behalf of the company's stockholders.

    10/26/2020CFRX
    ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients

    YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staph...

    10/1/2020CFRX
    We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

    09/9/2020CFRX
    ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference

    YONKERS, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a Fireside Chat at the 2020 Cantor...